Skip to main content

Table 4 Multivariable model of afatinib starting dose and WBRT pre afatinib on PFS in BM+ patients at start of afatinib. The relationship between starting dose, WBRT pre-afatinib and PFS in patients with BM shown in a multivariable model

From: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Multivariable analysis

Hazard ratio (95% CI)

p-value

Brain RT pre-afatinib

 No

1

 

 Yes

2.79 (0.93, 8.35)

0.062

Starting dose

 30 mg

1

 

 40 mg

0.22 (0.07, 0.67)

0.006